Why Levothyroxine Stops Working (The Conversion Problem Nobody Tests)

Most people on levothyroxine are told their thyroid problem is solved once their TSH comes back in range. The prescription is filled, the labs look normal, and yet a large number of these patients still feel exhausted, cold, mentally foggy, and heavy in a way they cannot explain. The medication is working. The problem is somewhere else entirely.

To understand where, you need the full map first.

Your thyroid gland produces two hormones: T4 and T3. T3 is the biologically active form, the one that actually enters your cells, binds to receptors in the nucleus, and drives the metabolic processes that determine your energy, your body temperature, your cognition, and your mood. T4, by contrast, is largely inactive on its own. It is better understood as a storage and transport molecule, a precursor that your body holds in reserve and converts into T3 as needed.

Here is the part that almost nobody explains clearly: your thyroid only produces about 20% of the T3 circulating in your body at any given time. The other 80% does not come from your thyroid at all. It comes from your liver, your kidneys, and your gut, where enzymes strip one iodine atom off a T4 molecule and convert it into active T3. This conversion process is what makes your circulating T3 levels what they are, and without it, you cannot function normally no matter how well your thyroid is producing T4.

Those conversion enzymes are called deiodinases, which are a family of proteins that exist specifically to regulate how much active thyroid hormone is available in different tissues at different times. They are not passive. They respond to the state of your body, and several things can suppress them significantly.

When a doctor prescribes levothyroxine, which is synthetic T4, the entire treatment model rests on the assumption that this conversion machinery is functioning normally. You take the T4, your body converts it, your T3 stays adequate, and you feel well. That is the theory. But the test most doctors run to monitor thyroid treatment is TSH, which stands for thyroid stimulating hormone, and TSH is a signal your pituitary gland sends to your thyroid to tell it to produce more hormone. When T4 levels are adequate, the pituitary sees enough hormone and TSH drops to normal range. The problem is that TSH reflects what the pituitary is sensing, not what is actually being converted and delivered to the rest of your body.

A 2022 analysis in The Lancet Diabetes and Endocrinology reviewed the evidence on levothyroxine-treated patients with normal TSH and found that these patients showed T3 to T4 ratios roughly 15 to 20% lower than people in the general population with healthy thyroid function. A 2019 survey of over 12,000 hypothyroid patients found that up to 40% remained symptomatic despite labs showing normal TSH. Normal TSH does not confirm adequate T3. It confirms adequate T4 feedback to the pituitary. Those are not the same thing.

So why does conversion fail in so many people on levothyroxine?

The deiodinase enzymes are selenoproteins, which means they require selenium as a structural component in order to function. Without adequate selenium, the enzymes cannot be built properly and conversion slows. Research in selenium-deficient patients has shown a measurable rise in the free T4 to T3 ratio, exactly the pattern you would expect if the enzymes responsible for that conversion were underperforming. This is not a minor effect. Selenium is not optional for this system.

Beyond selenium, chronic inflammation suppresses deiodinase activity directly. The inflammatory signaling molecules that circulate during chronic illness, autoimmune disease, or gut dysbiosis essentially downregulate the conversion pathway as part of a broader shift in how the body allocates resources when it senses threat. This is one reason why people with Hashimoto's thyroiditis, which is the autoimmune condition that causes most cases of hypothyroidism in developed countries, face a compounded problem. Hashimoto's destroys thyroid tissue, which reduces the 20% of T3 the thyroid produces directly. But the autoimmune inflammation it generates simultaneously suppresses peripheral conversion of the T4 that remains, cutting into the 80% as well. You lose from both ends.

Then there is a genetic layer on top of that. Between 12 and 36% of people carry a variant in something called the DIO2 gene, which codes for one of the deiodinase enzymes responsible for T4 to T3 conversion. Research published in the Journal of Clinical Endocrinology and Metabolism found that people with this variant scored significantly lower on measures of psychological well-being when treated with T4 alone, and that they responded substantially better to combination therapy that included both T4 and T3. The variant reduces conversion efficiency, and for people who carry it, no amount of T4 optimization will fully compensate for what the enzyme cannot do.

The practical application of all of this is straightforward. If you are on levothyroxine and still symptomatic, the first step is to ask your doctor to run a free T3 level alongside TSH. Free T3 reflects the actual amount of active hormone available in your bloodstream after conversion has happened. A low or low-normal free T3 in the presence of a normal TSH is the fingerprint of a conversion problem, and it is something TSH alone will never catch.

If conversion is impaired and selenium deficiency is contributing, 200 micrograms of selenium per day is a dose that has been studied specifically in the context of thyroid function, though this is worth discussing with a provider who understands your full picture before starting. If inflammation or gut dysfunction is driving the suppression, those are separate levers that need their own attention.

For people with confirmed DIO2 variants or persistent low T3 despite adequate T4, combination therapy using both levothyroxine and liothyronine, which is synthetic T3, represents a legitimate clinical option backed by evidence, though it is still underutilized because most protocols were written around TSH normalization rather than T3 adequacy.

The underlying shift here is not about distrusting levothyroxine. It is a good medication and it does exactly what it is designed to do. The issue is that the treatment model was built around a test that measures one checkpoint in a multi-step system, and for a large fraction of patients, the failure is happening at a checkpoint that test does not see.

Treating a lab value and treating the body are not always the same thing, and for thyroid patients, the distance between those two things can span years of symptoms that were always real and never found on paper.

---

References

1. Bianco AC, Kim BW. Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest. 2006;11610:2571-2579. PMID: 17016550. Source
2. Endotext NCBI Bookshelf. Thyroid Hormone Synthesis and Secretion: "The thyroid gland produces approximately 20% of total daily T3 production, with the remaining 80% arising from peripheral deiodination of T4." Source
3. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022;10(5):366-372. DOI: 10.1016/S2213-8587(22)00004-3.
4. Peterson SJ, Cappola AR, Castro MR, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2019;295:707-721. PMID: 29620972. Source
5. Panicker V, Saravanan P, Vaidya B, et al. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy. JCEM. 2009;945:1623-1629. PMID: 19190113. Source
6. Kobayashi R, Hasegawa Y, Kawaguchi T, et al. Thyroid function in patients with selenium deficiency exhibits high free T4 to T3 ratio. Clin Pediatr Endocrinol. 2021;30(1):19-26. DOI: 10.1297/cpe.30.19.
7. Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. PMID: 28255299. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness